OxRML/AgentSLR huggingface dataset:
Parameter: Severity - case fatality rate (CFR) (Severity)
Value: 0.04 Percentage (%) (Central)
Exponent (base 10): 0
Case definition: Unspecified
Numerator/denominator:  /  (method: Unspecified)
Statistical approach: Observed sample statistic
Reproduction number method:  Unspecified
Population: General population, sex: Unspecified, ages  to 
Country: Dominican Republic
Setting: Population based, 
Sample size: 5161
Study period: 2016
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 23 Percentage (%) ()
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 118 / 508 (method: Naive)
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Persons under investigation, sex: Both, ages  to 
Country: Philippines
Setting: Hospital based, 
Study period: 2016
Parameter: Seroprevalence - HAI/HI (Seroprevalence)
Value: 52.6 Percentage (%) ()
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 235 / 447 (method: Naive)
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Disaggregated by: Age
Population: Other, sex: Both, ages 18 to 
Country: Brazil
Location: Manaus
Setting: Community based, Urban area
Sample size: 447
Study period: Jan 2015 - Dec 2015
Parameter: Seroprevalence - MIA (Seroprevalence)
Value:  Percentage (%) (Mean)
Exponent (base 10): 0
Bounds: 0 - 45.6
Statistical approach: Observed sample statistic
Disaggregated by: Region
Population: General population, sex: Both, ages 2 to 75
Country: France
Location: French Guiana
Setting: Population based, 
Sample size: 2697
Study period: Jun 2017 - Oct 2017
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 31.4 Percentage (%) (Central)
Exponent (base 10): 0
Numerator/denominator: 49 / 156 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Other, sex: Unspecified, ages  to 
Country: Paraguay
Location: Central department and Asuncion
Setting: Hospital based, Both urban and rural areas
Sample size: 156
Study period: Jan 2018 - May 2018
Parameter: Seroprevalence - IgM (Seroprevalence)
Value: 0 Percentage (%) ()
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 0 / 150 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Persons under investigation, sex: Both, ages  to 
Country: China
Location: Affiliated Hospital of Jining Medical University
Setting: Hospital based, Both urban and rural areas
Sample size: 150
Study period: Oct 2013 - Jun 2017
Parameter: Seroprevalence - IgM (Seroprevalence)
Value: 44 Percentage (%) (Unspecified)
Exponent (base 10): 0
Bounds: 0 - 97
Case definition: Lab confirmed
Numerator/denominator: 27 / 61 (method: Naive)
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Disaggregated by: Other
Trimester exposed: Unspecified
Population: Pregnant women, sex: Female, ages  to 
Country: United States
Location: Congenital Zika Program at Children’s National (CZPCN) in Washington DC
Setting: Hospital based, Unspecified
Sample size: 61
Study period: Jan 2016 - Jun 2018
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Value: 8 Percentage (%) (Unspecified)
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 2 / 26 (method: Naive)
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Trimester exposed: Unspecified
Population: Pregnant women, sex: Female, ages  to 
Country: United States
Location: Congenital Zika Program at Children’s National (CZPCN) in Washington DC
Setting: Hospital based, Unspecified
Sample size: 26
Study period: Jan 2016 - Jun 2018
Parameter: Seroprevalence - IgM (Seroprevalence)
Value: 16 Percentage (%) (Unspecified)
Exponent (base 10): 0
Bounds: 0 - 33
Case definition: Lab confirmed
Numerator/denominator: 5 / 31 (method: Naive)
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Disaggregated by: Other
Trimester exposed: Unspecified
Population: Children, sex: Unspecified, ages  to 
Country: United States
Location: Congenital Zika Program at Children’s National (CZPCN) in Washington DC
Setting: Hospital based, Unspecified
Sample size: 31
Study period: Jan 2016 - Jun 2018
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Value: 0 Percentage (%) (Unspecified)
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 0 / 5 (method: Naive)
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Trimester exposed: Unspecified
Population: Children, sex: Unspecified, ages  to 
Country: United States
Location: Congenital Zika Program at Children’s National (CZPCN) in Washington DC
Setting: Hospital based, Unspecified
Sample size: 5
Study period: Jan 2016 - Jun 2018
Parameter: Severity - proportion of symptomatic cases (Severity)
Value: 24 Percentage (%) (Unspecified)
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 7 / 29 (method: Naive)
Statistical approach: Observed sample statistic
Trimester exposed: Unspecified
Population: Pregnant women, sex: Female, ages  to 
Country: United States
Location: Congenital Zika Program at Children’s National (CZPCN) in Washington DC
Setting: Hospital based, Unspecified
Sample size: 29
Study period: Jan 2016 - Jun 2018
Parameter: Seroprevalence - IgM (Seroprevalence)
Value: 29.4 Percentage (%) ()
Exponent (base 10): 0
Numerator/denominator: 53 / 180 (method: )
Population: Pregnant women, sex: Female, ages 19 to 48
Country: Nigeria
Location: Zaria
Setting: Hospital based, Both urban and rural areas
Sample size: 180
Study period: Unspecified
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 83.6 Percentage (%) (Unspecified)
Exponent (base 10): 0
Bounds: 70 - 100
Case definition: Lab confirmed
Numerator/denominator: 51 / 61 (method: Naive)
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Disaggregated by: Age, Sex
Trimester exposed: Unspecified
Population: General population, sex: Both, ages 18 to 69
Country: Thailand
Location: Nakhon Ratchasima
Setting: Population based, Unspecified
Sample size: 61
Study period: Apr 2016 - Jun 2016
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Value: 44.3 Percentage (%) (Unspecified)
Exponent (base 10): 0
Bounds: 35 - 75
Case definition: Lab confirmed
Numerator/denominator: 27 / 61 (method: Naive)
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Disaggregated by: Age, Sex
Trimester exposed: Unspecified
Population: General population, sex: Both, ages 18 to 69
Country: Thailand
Location: Nakhon Ratchasima
Setting: Population based, Unspecified
Sample size: 61
Study period: Apr 2016 - Jun 2016
Parameter: Seroprevalence - IgM (Seroprevalence)
Value: 3.2 Percentage (%) (Unspecified)
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 6 / 189 (method: Naive)
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Trimester exposed: Unspecified
Population: Other, sex: Both, ages 20 to 
Country: Dominican Republic
Setting: Travel based, Unspecified
Sample size: 189
Study period: 2016 - Unspecified
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Value: 3.2 Percentage (%) (Unspecified)
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 6 / 6 (method: Naive)
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Trimester exposed: Unspecified
Population: Other, sex: Both, ages 20 to 
Country: Dominican Republic
Setting: Travel based, Unspecified
Sample size: 189
Study period: 2016 - Unspecified
Parameter: Seroprevalence - IgM (Seroprevalence)
Value: 63 Percentage (%) (Unspecified)
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 19 / 30 (method: Naive)
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Trimester exposed: Unspecified
Population: Persons under investigation, sex: Both, ages 18 to 
Country: United States
Location: Miami-Dade County, Florida
Setting: Other, Unspecified
Sample size: 30
Study period: Unspecified
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 0.9 Percentage (%) (Unspecified)
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 5 / 577 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Trimester exposed: Unspecified
Population: Mixed groups, sex: Unspecified, ages  to 
Country: Kenya
Location: Eldoret, Kisumu, Nairobi
Setting: Population based, Unspecified
Sample size: 577
Study period: Mar 2009 - Jan 2014
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 0 / 11 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Trimester exposed: Unspecified
Population: Persons under investigation, sex: Unspecified, ages  to 
Country: Kenya
Location: Eldoret, Kisumu, Nairobi
Setting: Population based, Unspecified
Sample size: 11
Study period: Mar 2009 - Jan 2014
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 0 Percentage (%) (Unspecified)
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 0 / 135 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Trimester exposed: Unspecified
Population: Other, sex: Unspecified, ages  to 
Country: Kenya
Location: Eldoret
Setting: Population based, Unspecified
Sample size: 135
Study period: Jan 2013 - Feb 2013
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 1.5 Percentage (%) (Unspecified)
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 2 / 134 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Trimester exposed: Unspecified
Population: Other, sex: Unspecified, ages  to 
Country: Kenya
Location: Kisumu
Setting: Population based, Unspecified
Sample size: 134
Study period: Dec 2013 - Jan 2014
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 0 Percentage (%) (Unspecified)
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 0 / 96 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Trimester exposed: Unspecified
Population: Other, sex: Unspecified, ages  to 
Country: Kenya
Location: Nairobi
Setting: Population based, Unspecified
Sample size: 96
Study period: Aug 2013 - Sep 2013
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 1.4 Percentage (%) (Unspecified)
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 3 / 212 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Trimester exposed: Unspecified
Population: Other, sex: Unspecified, ages  to 
Country: Kenya
Location: Nairobi
Setting: Population based, Unspecified
Sample size: 212
Study period: Mar 2009 - Nov 2012
Parameter: Seroprevalence - IgM (Seroprevalence)
Value: 4.9 Percentage (%) (Unspecified)
Exponent (base 10): 0
Uncertainty: 3.5 - 6.6 (95% CI)
Bounds: 1.2 - 35.4
Case definition: Lab confirmed
Numerator/denominator: 42 / 850 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Disaggregated by: Age, Sex, Time
Population: Other, sex: Both, ages 0 to 
Country: Mozambique
Setting: Population based, Both urban and rural areas
Sample size: 850
Study period: 2009 - 2015
Parameter: Seroprevalence - IgM (Seroprevalence)
Value: 6.6 Percentage (%) (Unspecified)
Exponent (base 10): 0
Uncertainty: 10.2 - 17 (95% CI)
Case definition: Lab confirmed
Numerator/denominator: 20 / 301 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Other, sex: Both, ages 0 to 
Country: Mozambique
Location: North Region
Setting: Population based, Unspecified
Sample size: 301
Study period: 2009 - 2015
Parameter: Seroprevalence - IgM (Seroprevalence)
Value: 4.7 Percentage (%) (Unspecified)
Exponent (base 10): 0
Uncertainty: 3.9 - 9 (95% CI)
Case definition: Lab confirmed
Numerator/denominator: 17 / 356 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Other, sex: Both, ages 0 to 
Country: Mozambique
Location: Central Region
Setting: Population based, Unspecified
Sample size: 356
Study period: 2009 - 2015
Parameter: Seroprevalence - IgM (Seroprevalence)
Value: 2.5 Percentage (%) (Unspecified)
Exponent (base 10): 0
Uncertainty: 8.5 - 17.4 (95% CI)
Case definition: Lab confirmed
Numerator/denominator: 5 / 193 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Other, sex: Both, ages 0 to 
Country: Mozambique
Location: South Region
Setting: Population based, Unspecified
Sample size: 193
Study period: 2009 - 2015
Parameter: Human delay - Onset to Test result (Human delay)
Value: 3.5 Days (Median)
Exponent (base 10): 0
Uncertainty: 3 - 5 (IQR)
Statistical approach: Observed sample statistic
Population: Persons under investigation, sex: Both, ages 1 to 71
Country: Thailand
Location: Bangkok, Samut Prakan, Samut Sakhon, Ratchaburi, Chon Buri
Setting: Hospital based, Unspecified
Sample size: 90
Study period: Mar 2020 - Mar 2023
Parameter: Mutations - substitution rate (Mutations)
Value: 7.95 Substitutions/site/year (Unspecified)
Exponent (base 10): -4
Statistical approach: Estimated model parameter
Genome site: Whole genome sequence
Genomic lineage: Asian lineage (Thai strains)
Population: Persons under investigation, sex: Unspecified, ages  to 
Country: Multi-country: Americas (n = 13), Asia: (n = 9), Oceania (n = 2)
Setting: Mixed settings, Unspecified
Sample size: 214
Study period: 1966 - 2023
Parameter: Seroprevalence - IgM (Seroprevalence)
Value: 3 Percentage (%) (Unspecified)
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 18 / 600 (method: Naive)
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Disaggregated by: Age, Other, Sex
Trimester exposed: Unspecified
Population: Other, sex: Both, ages 20 to 
Country: Taiwan
Setting: Travel based, Unspecified
Sample size: 600
Study period: Jun 2017 - Aug 2017
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 38.8 Percentage (%) (Unspecified)
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator:  / 600 (method: Naive)
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Disaggregated by: Age, Other, Sex
Trimester exposed: Unspecified
Population: Other, sex: Both, ages 20 to 
Country: Taiwan
Setting: Travel based, Unspecified
Sample size: 600
Study period: Jun 2017 - Aug 2017
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 30.77 Percentage (%) (Unspecified)
Exponent (base 10): 0
Bounds: 18.75 - 50
Case definition: Lab confirmed
Numerator/denominator: 200 / 650 (method: )
Seroprevalence adjustment: Unspecified
Statistical approach: Observed sample statistic
Disaggregated by: Age, Other, Time
Population: Pregnant women, sex: Female, ages 18 to 45
Country: Thailand
Location: Siriraj Hospital
Setting: Hospital based, Unspecified
Sample size: 650
Study period: May 2019 - Oct 2019
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Value: 8.14 Percentage (%) (Unspecified)
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 21 / 258 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Pregnant women, sex: Female, ages 18 to 45
Country: Thailand
Location: Siriraj Hospital
Setting: Hospital based, Unspecified
Sample size: 258
Study period: May 2019 - Oct 2019
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 68 Percentage (%) (Unspecified)
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 127 / 188 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Trimester exposed: Unspecified
Population: Pregnant women, sex: Female, ages  to 
Country: Brazil
Location: Salvador, Bahia
Setting: Hospital based, Urban area
Sample size: 188
Study period: 1 Jan 2015 - 31 Jan 2017
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 64 Percentage (%) (Median)
Exponent (base 10): 0
Uncertainty: 61 - 67 (IQR)
Case definition: Lab confirmed
Seroprevalence adjustment: Adjusted
Statistical approach: Estimated model parameter
Trimester exposed: Unspecified
Population: Pregnant women, sex: Female, ages  to 
Country: Brazil
Location: Salvador, Bahia
Setting: Hospital based, Urban area
Sample size: 188
Study period: 1 Jan 2015 - 31 Jan 2017
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 19 Percentage (%) (Unspecified)
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 43 / 227 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Trimester exposed: Unspecified
Population: Pregnant women, sex: Female, ages  to 
Country: Brazil
Location: Salvador, Bahia
Setting: Hospital based, Urban area
Sample size: 227
Study period: 1 Jan 2015 - 31 Jan 2017
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 19 Percentage (%) (Median)
Exponent (base 10): 0
Uncertainty: 16 - 22 (IQR)
Case definition: Lab confirmed
Seroprevalence adjustment: Adjusted
Statistical approach: Estimated model parameter
Trimester exposed: Unspecified
Population: Pregnant women, sex: Female, ages  to 
Country: Brazil
Location: Salvador, Bahia
Setting: Hospital based, Urban area
Sample size: 227
Study period: 1 Jan 2015 - 31 Jan 2017
Parameter: Seroprevalence - MIA (Seroprevalence)
Value: 30.3 Percentage (%) (Unspecified)
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 121 / 400 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Persons under investigation, sex: Unspecified, ages  to 
Country: Panama
Setting: Population based, Unspecified
Sample size: 400
Study period: 2015 - 2016
Parameter: Seroprevalence - IgM (Seroprevalence)
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 1 / 16 (method: )
Seroprevalence adjustment: Naive
Trimester exposed: Unspecified
Population: Persons under investigation, sex: Both, ages  to 
Country: Brazil
Location: Northeast Brazil
Setting: Hospital based, Unspecified
Sample size: 16
Study period: Dec 2014 - Feb 2017
Parameter: Seroprevalence - IgM (Seroprevalence)
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 3 / 15 (method: )
Seroprevalence adjustment: Naive
Trimester exposed: Unspecified
Population: Persons under investigation, sex: Unspecified, ages  to 
Country: Brazil
Location: Northeast Brazil
Setting: Hospital based, Unspecified
Sample size: 15
Study period: Dec 2014 - Feb 2017
Parameter: Seroprevalence - IgM (Seroprevalence)
Exponent (base 10): 0
Case definition: Lab confirmed
Numerator/denominator: 17 / 68 (method: Naive)
Seroprevalence adjustment: Naive
Trimester exposed: Unspecified
Population: Persons under investigation, sex: Both, ages  to 
Country: Brazil
Location: Northeast Brazil
Setting: Hospital based, Unspecified
Sample size: 68
Study period: Dec 2014 - Feb 2017
Parameter: Attack rate (Attack rate)
Value:  Percentage (%) (Unspecified)
Exponent (base 10): 0
Bounds: 0 - 0.9
Disaggregated by: Method, Other
Population: General population, sex: Both, ages  to 
Country: Netherlands
Setting: Travel based, Unspecified
Sample size: 481
Study period: Mar 2014 - Oct 2017
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 14 Percentage (%) ()
Exponent (base 10): 0
Uncertainty: 8.5 - 21 ()
Numerator/denominator: 18 / 129 (method: Naive)
Population: General population, sex: Both, ages  to 
Country: Netherlands
Setting: Travel based, Unspecified
Sample size: 129
Study period: Mar 2014 - Oct 2017
Parameter: Seroprevalence - IgG (Seroprevalence)
Value: 0.6 Percentage (%) ()
Exponent (base 10): 0
Uncertainty: 0.1 - 2.1 (95% CI)
Numerator/denominator: 2 / 326 (method: Naive)
Population: General population, sex: Both, ages  to 
Country: Netherlands
Setting: Travel based, Unspecified
Sample size: 326
Study period: Mar 2014 - Oct 2017
Parameter: Risk factors (Risk factors)
Exponent (base 10): 0
Uncertainty: 0.1 - 2.1 (95% CI)
Risk factor: Age;Other (outcome: Serology; significant: Significant; adjusted: Not adjusted; occupation: )
Population: General population, sex: Both, ages  to 
Country: Unspecified
Setting: Travel based, Unspecified
Sample size: 455
Study period: Mar 2014 - Oct 2017
Parameter: Risk factors (Risk factors)
Exponent (base 10): 0
Uncertainty: 0.1 - 2.1 (95% CI)
Risk factor: Other;Sex (outcome: Serology; significant: Not significant; adjusted: Not adjusted; occupation: )
Population: General population, sex: Both, ages  to 
Country: Unspecified
Setting: Travel based, Unspecified
Sample size: 455
Study period: Mar 2014 - Oct 2017
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Value: 29.7 Percentage (%) ()
Exponent (base 10): 0
Uncertainty: 23.3 - 26 (95% CI)
Numerator/denominator: 385 / 499 (method: Adjusted)
Seroprevalence adjustment: Adjusted
Population: Mixed groups, sex: Both, ages  to 
Country: Thailand
Location: Narathiwat
Setting: Household based, 
Sample size: 499
Study period: Mar 2018 - Sep 2018
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Value: 24.3 Percentage (%) ()
Exponent (base 10): 0
Uncertainty: 20.1 - 28.8 (95% CI)
Population: Pregnant women, sex: Both, ages  to 
Country: Thailand
Location: Surat Thani
Setting: Household based, 
Study period: Jul 2018 - Mar 2019
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Value: 12.8 Percentage (%) ()
Exponent (base 10): 0
Uncertainty: 9.7 - 16.5 (95% CI)
Population: Pregnant women, sex: Both, ages  to 
Country: Thailand
Location: Narathiwat
Setting: Household based, 
Study period: Jul 2018 - Mar 2019
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Value: 43.7 Percentage (%) ()
Exponent (base 10): 0
Uncertainty: 35.9 - 51.6 (95% CI)
Numerator/denominator: 377 / 504 (method: )
Population: Mixed groups, sex: Both, ages  to 
Country: Thailand
Location: Surat Thani
Setting: Household based, 
Sample size: 504
Study period: Mar 2018 - Sep 2018
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Exponent (base 10): 0
Numerator/denominator: 2 / 263 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Other, sex: , ages  to 
Country: Mexico
Location: Guerrero
Setting: Hospital based, Unspecified
Sample size: 48
Study period: May 2019 - Nov 2019
Parameter: Seroprevalence - Neutralisation/PRNT (Seroprevalence)
Exponent (base 10): 0
Numerator/denominator: 6 / 263 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Other, sex: , ages  to 
Country: Mexico
Location: Guerrero
Setting: Hospital based, Unspecified
Sample size: 60
Study period: May 2019 - Nov 2019
Parameter: Seroprevalence - IgG (Seroprevalence)
Value:  Percentage (%) ()
Exponent (base 10): 0
Uncertainty: 0 - 16.74 (95% CI)
Bounds: 0 - 5.35
Seroprevalence adjustment: Naive
Disaggregated by: Time
Population: General population, sex: Unspecified, ages  to 
Country: Colombia
Location: Barranquilla
Setting: Population based, Unspecified
Sample size: 390
Study period: 6 May 2015 - 31 Aug 2015
Parameter: Seroprevalence - IgM (Seroprevalence)
Value:  Percentage (%) (Central)
Exponent (base 10): 0
Bounds: 1.7 - 66.3
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Disaggregated by: Method
Population: Children, sex: Unspecified, ages  to 
Country: Honduras
Location: Tegucigalpa
Setting: Hospital based, Urban area
Sample size: 60
Study period: Jul 2016 - Dec 2016
Parameter: Seroprevalence - IgM (Seroprevalence)
Exponent (base 10): 0
Numerator/denominator: 9 / 43 (method: )
Seroprevalence adjustment: Naive
Statistical approach: Observed sample statistic
Population: Pregnant women, sex: Female, ages  to 
Country: Brazil
Location: Central-West
Setting: Hospital based, Unspecified
Sample size: 43
Study period: Jan 2017 - Apr 2019